Abstract

This study seeks to examine the effectiveness and safety of lacosamide in treating pediatric individuals with focal seizures. 120 children diagnosed with either new-onset or refractory focal seizures involved in the study and were randomly allocated into either the control or observation group. Conventional treatment, comprising oral oxcarbazepine, was administered to the control group, whereas the observation group received lacosamide in addition to conventional treatment. Both sets of participants were administered medication for a period of 12 mo. A comparison was made in terms of seizure frequency, treatment effectiveness, intelligence quotient levels, quality of life ratings, and adverse reactions between groups. Prior to treatment, there was no notable contrast in seizure frequency between the groups (p>0.05). Nonetheless, following 6 and 12 mo of treatment, the observation group demonstrated notably decreased seizure frequency as opposed to the control group (p<0.05). The overall treatment effectiveness in the observation group stood considerably higher than that of the control group (p<0.05). Although no discernible disparities in intelligence quotient levels was observed prior to treatment (p>0.05), posttreatment, the intelligence quotient level was notably elevated in the observation group as opposed to the control group, with noteworthy improvement observed in both groups in relative to pre-treatment levels (p<0.05). No remarkable difference was found in the scores of physiological function, school function, emotional function, and social function prior to treatment (p>0.05). Subsequent to treatment, the observation group exhibited markedly elevated scores, and both groups revealed substantial progress from their scores before treatment (p<0.05). The occurrence of adverse reactions did not demonstrate noteworthy differences between groups (p>0.05). The combined administration of lacosamide and oxcarbazepine displayed superior effectiveness in managing focal seizures in pediatric patients compared to the use of oxcarbazepine alone. It caused a marked reduction in seizure frequency and had a favorable impact on the intellectual capacity and life quality of the patients. Lacosamide maintained a positive safety profile, with no noticeable increase in adverse reaction frequency.